Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cencora, Inc. Common Stock (NY:COR)

299.42 +2.84 (+0.96%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cencora, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data. 
Via Benzinga
Earnings Scheduled For February 5, 2025
Via Benzinga
$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Breaking Down Cencora: 6 Analysts Share Their Views
Via Benzinga
Looking Into Cencora's Recent Short Interest
Via Benzinga
Cencora Q1 Earnings: Revenue And EPS Beat On Strong Push From Obesity Drugs, Specialty Medicines
Cencora posted Q1 sales of $81.5 billion, exceeding forecasts, with strong GLP-1 drug sales. Adjusted EPS beat estimates, and FY25 guidance was raised. 
Via Benzinga
Cencora (NYSE:COR) Reports Upbeat Q4
Healthcare distributor Cencora (NYSE:COR) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 12.8% year on year to $81.49 billion. Its non-GAAP profit of $3.73 per... 
Via StockStory
Cencora Reports Fiscal 2025 First Quarter Results
From Cencora
Via Business Wire
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60. 
Via Benzinga
Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
(COR) - Analyzing Cencora's Short Interest
Via Benzinga
$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release
From Cencora
Via Business Wire
Cencora Completes Acquisition of Retina Consultants of America
From Cencora
Via Business Wire
Cencora Closes $1.8 Billion Senior Notes Offering
From Cencora
Via Business Wire
Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035
From Cencora
Via Business Wire
Looking Into Cencora's Recent Short Interest
Via Benzinga
McKesson Stock Gets A RS Rating Lift To 75
The Relative Strength (RS) Rating for McKesson stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75. 
Via Investor's Business Daily
Cardinal Health Stock Sees IBD RS Rating Improve To 71
In a welcome move, Cardinal Health stock saw its Relative Strength (RS) Rating rise from 65 to 71 on Friday. 
Via Investor's Business Daily
Deep Dive Into Cencora Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Trump's Win Sends Indices To Record Highs; Financials, Small Caps Surge, Bitcoin Tops $75,000: What's Driving Markets Wednesday?
An “everything rally” powered Wall Street on Wednesday after the 2024 election results, with Donald Trump emerging as the clear presidential winner. 
Via Benzinga
Topics Government
Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings
Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal years 2027 and 2028. 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,700 Today
Via Benzinga
Analyst Scoreboard: 6 Ratings For Cencora
Via Benzinga
Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results
From Cencora
Via Business Wire
Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America
From Cencora
Via Business Wire
Cencora Expands Enterprise Leadership Team with Two Senior Appointments
From Cencora
Via Business Wire
Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy
Walgreens Boots Alliance (WBA) is down 60% from its 52-week high, but improving earnings, cost cuts, and a 9.27% dividend yield signal potential recovery. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.